Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Ribociclib and Letrozole Treatment in Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 51
- Registration Number
- NCT03673124
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Saint Vincent Hospital and Health Care Center, Inc., Indianapolis, Indiana, United States
🇺🇸The Ohio State Comprehensive Cancer Center, Columbus, Ohio, United States
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 327
- Registration Number
- NCT03671330
- Locations
- 🇨🇳
Novartis Investigative Site, Tianjin, China
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
- Conditions
- Interventions
- First Posted Date
- 2018-08-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 147
- Registration Number
- NCT03644186
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷Centre Léon Berard, Lyon, France
🇮🇹Centro di Riferimento Oncologico (CRO), Via Franco Gallini 2, Aviano, Pordenone, Italy
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 93
- Registration Number
- NCT03633331
- Locations
- 🇺🇸
Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States
🇺🇸Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States
🇺🇸Kootenai Cancer Center, Post Falls, Idaho, United States
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 24
- Registration Number
- NCT03628066
- Locations
- 🇨🇦
Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
🇺🇸Saddleback Memorial Medical Center, Laguna Hills, California, United States
🇺🇸West Virginia University, Morgantown, West Virginia, United States
A Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth in Women With PCOS
- Conditions
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Hongxia Ma
- Target Recruit Count
- 1100
- Registration Number
- NCT03625531
- Locations
- 🇨🇳
The first affiliated hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 56
- Registration Number
- NCT03555877
- Locations
- 🇩🇪
Studienzentrum Onkologie Ravensburg, Ravensburg, Germany
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Invasive Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8HER2/Neu NegativeAnatomic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 20
- Registration Number
- NCT03554044
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Endometrial Preparation in Frozen Embryo Transfer Cycles
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- Meir Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT03540979
Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- National Cancer Center, Korea
- Target Recruit Count
- 114
- Registration Number
- NCT03497702
- Locations
- 🇰🇷
National Cancer Center, Goyang-si, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.